150 related articles for article (PubMed ID: 26619297)
1. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
Goldstein DA; Zeichner SB
Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297
[TBL] [Abstract][Full Text] [Related]
2. The Systemic Management of Advanced Melanoma in 2016.
Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
[TBL] [Abstract][Full Text] [Related]
3. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
[TBL] [Abstract][Full Text] [Related]
5. NICE approves immunotherapy combination for advanced melanoma.
Wise J
BMJ; 2016 Jun; 353():i3421. PubMed ID: 27317590
[No Abstract] [Full Text] [Related]
6. Comparative healthcare costs in patients with metastatic melanoma in the USA.
Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
8. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
9. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
10. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
11. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
12. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
13. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
14. Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Tsai KK; Daud AI
J Hematol Oncol; 2015 Oct; 8():123. PubMed ID: 26518223
[TBL] [Abstract][Full Text] [Related]
15. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
16. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for metastatic melanoma.
Chandra S; Pavlick AC
Dermatol Clin; 2012 Jul; 30(3):517-24. PubMed ID: 22800555
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
19. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for treatment of refractory melanoma.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e419. PubMed ID: 25328942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
